Fiche publication
Date publication
juillet 2016
Journal
Expert review of anticancer therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Amaral T, Nouri N, Garbe C
Lien Pubmed
Résumé
In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 mutations. This paper addresses the safety and efficacy of cobimetinib, when used in combination with vemurafenib, in the previous mentioned setting.
Mots clés
BRAF mutated metastatic melanoma, BRAF mutation, BRAF/MEK inhibition, Cobimetinib, MAPK pathway, combination targeted therapy
Référence
Expert Rev Anticancer Ther. 2016 07;16(7):705-15
